Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback